Navigation Links
$1.8 million grant supports investigation of psoriasis link to cardiovascular disease
Date:9/20/2012

Armed with a new $1.8 million grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases, dermatology researcher Nicole Ward, PhD, assistant professor of dermatology and neurosciences at Case Western Reserve School of Medicine, will lead a study examining the link between psoriasis and heart attack and stroke.

The work will advance research conducted earlier this year in Dr. Ward's lab. She and colleagues at the University Hospitals Harrington Heart & Vascular Institute, published a major discovery that psoriasis could cause the development of cardiovascular disease in mouse models. The team of researchers also found that aggressive treatment of the skin disease reversed the cardiovascular disease.

"Prior to our recent publication, the evidence linking these two diseases was entirely at the epidemiological level and didn't show mechanistic insight for why this occurred," says Dr. Ward, who is also a scientist with the Murdough Family Center for Psoriasis at University Hospitals Case Medical Center. "Our goal was to examine whether psoriasis influences cardiovascular disease. Psoriasis was previously thought of as a disease that severely affected skin appearance as well as the patient's quality of life. We now know it decreases a patient's life span by seven years."

Dr. Ward and colleagues will work to identify intrinsic changes in the skin cells and the subsequent cascade of events that leads to blood-clot formation in either heart attack or stroke. By identifying this trigger, the researchers hope to provide first-ever evidence that cell-specific events in psoriasis can be targeted for treatment.

This preclinical evidence will impact the approach to patient clinical care, as doctors will need to be more aggressive in monitoring for cardiovascular disease and other co-morbidities in those with moderate to severe-plaque psoriasis. By treating and keeping the skin disease in check, the risk for heart-related inflammation is reduced as well. In addition, they will conduct preclinical testing of the efficacy of current psoriasis medication on cardiovascular disease.

"Dr. Ward's research discovery is quite exciting," says Kevin Cooper, MD, professor and chair of the Department of Dermatology at Case Western Reserve School of Medicine and University Hospitals Case Medical Center, "It demonstrates for the first time that a mouse model of psoriasis exhibits a cardiovascular co-morbidity often seen in human psoriasis patients. Importantly, the basis of Dr. Ward's grant demonstrates that aggressively treating the skin disease improved the cardiovascular complications associated with psoriasis. The work supported by this grant will help to pinpoint how current therapeutics for psoriasis may also improve co-morbidities associated with chronic skin inflammation."


'/>"/>

Contact: Jessica Studeny
jessica.studeny@case.edu
216-368-4692
Case Western Reserve University
Source:Eurekalert

Related medicine news :

1. Systems biologist receives $2.5 million Pioneer Award for genome research
2. Scripps Research Institute receives $20 million to shed light on HIV drug resistance
3. FEMA awards $1 Million to WPI to develop groundbreaking toxic gas sensors for firefighters
4. IU optometrist receives $1.9 million to assess street-crossing program
5. Moffitt Cancer Center researcher receives $2.1 million grant from NCI for answering Provocative Question
6. Scientist receives $2.8 Million to study cell signaling mechanism and develop potential therapeutics
7. Nearly $50 million in research funding awarded by NSF
8. $8.9 million NIH grant to study genomic link to premature heart disease
9. UCF nanoscientist receives $2 million NIH award
10. Saving brains in developing countries: $11.8 million for innovative ideas worldwide
11. Funding for neglected global diseases research at UBC exceeds $20 million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/26/2017)... ... 26, 2017 , ... Global healthcare company Novo Nordisk, renewed ... company’s commitment to the world’s first all-diabetes professional cycling team to a total ... partnered with the professional cycling team Team Type 1 to create Team Novo ...
(Date:9/26/2017)... ... September 26, 2017 , ... After a summer-long contest ... Campaign for Designated Drivers proudly announced the winners of the HEROtini Mocktail Challenge ... restaurants took on the challenge of competing in three categories: Best HEROtini Mocktail, ...
(Date:9/26/2017)... ... September 26, 2017 , ... ... expands services in Northern Colorado. Aspire Autism, A Division of Autism Learning Partners, ... Analysis (ABA) services. Aspire provides center based Autism services in Broomfield and will ...
(Date:9/26/2017)... ... September 26, 2017 , ... “Good Morning Sunshine!: Finding Strength and Comfort ... “Good Morning Sunshine!: Finding Strength and Comfort in God” is the creation of published ... Hays Sate University, who has worked at a local mental health center for over ...
(Date:9/26/2017)... ... , ... “The Tour Guide”: is the life story of the author and the exciting times ... Alexander Stark, is an adventure tour guide and the subject of the book. , ... confront fifteen shocked faces. I played it off as a part of the adventure tour, ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... INDIANAPOLIS , Sept. 6, 2017 Eli ... today it will present new data for galcanezumab and ... Congress of the International Headache Society (IHC) taking place ... Lilly will highlight new, long-term data from ... two doses of galcanezumab (120 mg and 240 mg) ...
(Date:9/5/2017)... 18 months after its February 2016 launch, market access ... of three new senior people to its rapidly expanding ... and James Wright bring decades of specialist ... Tammy Wynne joins as Director, Value Communication, ... over ten years, experience in global market access consultancy ...
(Date:9/1/2017)... 2017  Bayer will present the latest research from across ... Oncology (ESMO) 2017 Congress, September 8-12 in Madrid, ... and clinical data on Bayer,s marketed portfolio and late-stage compounds ... "We value the opportunity ... research at ESMO," said Carsten Brunn , Head of ...
Breaking Medicine Technology: